How much funding has Regenovo raised?

Regenovo has raised $5M in total funding. Key investors include Shining3D (majority shareholder with 55% stake); Hangzhou University of Science and Technology; Zhejiang Provincial Government; Hangzhou Municipal Government; Private investors.

Who is the CEO of Regenovo?

Xu Mingen is the CEO of Regenovo. The company was founded in 2013.

Where is Regenovo located?

Regenovo is headquartered in Hangzhou, China.

What funding stage is Regenovo at?

Regenovo is currently at the Active stage.

How many employees does Regenovo have?

Regenovo has approximately 11-50 employees.

Regenovo

Name: AM Companies Database
Creator: AMPulse
License: https://creativecommons.org/licenses/by/4.0/

HardwareHangzhou, ChinaFounded 2013· One of 1708 Hardware companies tracked by AMPulse

Develops medical-grade 3D bioprinters and bioinks for creating living tissue scaffolds, enabling applications in drug screening, regenerative medicine, and personalized medical devices

CEO / Founder: Xu Mingen
Team Size: 11-50
Stage: Active
Total Funding: $5M
Latest Round: Seed
Key Investors: Shining3D (majority shareholder with 55% stake); Hangzhou University of Science and Technology; Zhejiang Provincial Government; Hangzhou Municipal Government; Private investors

Technology & Products

Key Products

Regenovo 3D Bioprinters (e.g., Bio-Architect X), bioinks, biomaterials, skin models, micro-liver models.

Technological Advantage

Patented technology for real-time cell microenvironment monitoring (verified); proprietary bioink formulations and precision control systems (claimed); complete digital medical chain from medical information to 3D printed medical products

Differentiation

Value Proposition

Provides complete biological 3D printing solutions from equipment to materials, reducing tissue engineering development time and enabling personalized medical treatments

How They Differentiate

Focus on real-time cell microenvironment monitoring (unique among competitors); complete solution from printers to biomaterials vs competitors' narrower focus; strong academic partnerships in China vs global competitors' different geographic focus

Market & Competition

Target Customers

Pharmaceutical companies, research institutions, hospitals, and medical device manufacturers

Industry Verticals

Pharmaceutical; Medical Research; Healthcare; Biotechnology

Competitors

Organovo, CELLINK, Rokit Healthcare

Growth & Milestones

Growth Metrics

Developed China's first commercial 3D bioprinter in 2013; Over 50 bioprinters installed in research institutions and hospitals across China; Published more than 100 research papers in bioprinting field; Received multiple national and provincial research grants

Major Milestones

Founded in 2013 as joint venture by Xiangli 3D; Developed world's first real-time cell microenvironment monitoring 3D printer; Hosted 5th Regenovo Biological 3D Printing Summit in 2021; Achieved national-level specialized and innovative enterprise status

Notable Customers

Hangzhou University of Science and Technology; Zhejiang University School of Medicine; Shanghai Ninth People's Hospital; Chinese Academy of Sciences

https://www.regenovo.com

Why this company matters

Regenovo positions itself as a complete biological 3D printing solutions provider, offering both equipment and materials to reduce tissue engineering development time. Founded in 2013 as a joint venture, it claims the world's first commercial 3D bioprinter in China and has since installed over 50 bioprinters in research institutions and hospitals across the country.

The company's core technology is material extrusion (MEX) bioprinting, applied through products like the Bio-Architect X printer. Its distinctive feature is real-time monitoring of cell microenvironments using combined OCT/ODT imaging, a capability verified by patents. Regenovo also develops proprietary bioinks and biomaterials, creating a dual-core industrial system linking biological 3D printing with biomaterials.

Customers include pharmaceutical companies, research institutions, and hospitals. Named partners include Hangzhou University of Science and Technology, Zhejiang University School of Medicine, Shanghai Ninth People's Hospital, and the Chinese Academy of Sciences. Applications span drug screening, regenerative medicine, and personalized medical devices, with published skin and micro-liver models.

Regenovo's strategic moat lies in its integrated printer-bioink platform and strong academic partnerships in China, differentiating it from global competitors like Organovo and CELLINK that focus more narrowly on bioinks or specific applications. However, its geographic concentration and reliance on government and academic funding—with $5 million raised from Shining3D and provincial sources—pose risks if commercial adoption outside research settings remains slow.